Theranostic liposomes containing conjugated polymer dots and doxorubicin for bio-imaging and targeted therapeutic delivery. Issue 3 (4th January 2016)

• Record Type: Journal Article
• Authors: Ma, Man; Lei, Mingzhu; Tan, Xiaoxiao; Tan, Fengping; Li, Nan
• Is Part Of: RSC advances. Volume 6:Issue 3(2016)
• Page Start: 1945
• Page End: 1957
• Publication Date: 2016-01-04
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c5ra24485d
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : This work was devoted to the development of a lipid-based theranostic nanoparticle able to simultaneously host conjugated polymer dots, doxorubicin (Dox) and folate acid (FA). Abstract : This work was devoted to the development of a lipid-based theranostic nanoparticle able to simultaneously host conjugated polymer dots, doxorubicin (Dox) and folate acid (FA). Poly(9, 9-dioctylfluorene-2, 7-diyl- co -benzothiadiazole) (PFBT) was chosen as the fluorescent probe because of its high brightness in in vitro cellular uptake studies and good biocompatibility in in vitro / in vivo toxicity experiments. The theranostic liposomes (PFBT–Dox–Lip–FA) exhibited a hydrodynamic size of 127.30 ± 3.20 (nm) with a zeta potential of −25.00 ± 2.00 (mV). Mostly importantly, the extent of Dox release at 24 h from PFBT–Dox–Lip–FA showed a satisfactory result under mild hyperthermia conditions compared with Dox–Lip–FA. Such rapid release led to a lower half maximal inhibitory concentration (IC50 ) in MCF-7 cells at 16.8 ± 4.5 (μg mL −1 ), whereas the IC50 of Dox–Lip–FA (37 °C) was 28.3 ± 3.7 (μg mL −1 ). The cellular uptake study also revealed higher drug accumulation in tumor cells for theranostic liposomes. In vivo studies of PFBT–Dox–Lip–FA on tumor-bearing mouse models revealed that the distribution of liposomes in the tumors could be indicated accurately by PFBT. Besides, tumor-bearing mice could be significantly inhibited by PFBT–Dox–Lip–FA. Together with its negligible in vivo toxicity, PFBT–Dox–Lip–FA is a useful system for simultaneous cancer diagnosis and targeted drug delivery.